DprE1 inhibitors – a prospective target for development of antituberculosis drugs
The article reviews and analyzes 63 scientific publications devoted to new classes of antituberculosis drugs – DprE1 inhibitors. Currently, compounds BTZ-043, PBTZ-169 (makozinone), TBA-7371 and OPC-167832 are tested at different stages of clinical trials. DprE1 inhibitors are promising drugs with ant...
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Russian |
| Publicado em: |
New Terra Publishing House
2022-06-01
|
| coleção: | Туберкулез и болезни лёгких |
| Assuntos: | |
| Acesso em linha: | https://www.tibl-journal.com/jour/article/view/1644 |